SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : Elan Corporation, plc (ELN) -- Ignore unavailable to you. Want to Upgrade?


To: Robohogs who wrote (6034)11/20/2004 9:25:29 PM
From: John Metcalf  Read Replies (1) | Respond to of 10345
 
I may have missed it, in my bonehead (but charming!) way. If pricing is 2X, more accurately, 2X less 1/2 production cost, and BIIB gets half, where is cannibalization of Avonex sales? How does that spank their bottom line?

My expectation is that better efficacy means larger sales, and BIIB has priced to a revs-neutral point.

What am I missing?